Vamorolone (drinkable suspension, 40 mg/ml) is a “dissociative” synthetic steroid developed by Santhera and ReveraGen for Duchenne muscular dystrophy (DMD), as an anti-inflammatory treatment alternative to conventional corticosteroids.
- The European Union has just approved the marketing authorisation for vamorolone in DMD patients from the age of 4, based on the results of four trials in patients aged between 4 and 7, including a comparative study with prednisone.
- The results of these studies of vamorolone point to positive functional effects similar to those of the corticosteroids normally used.
- The drug will be marketed in Europe gradually, with Germany leading the way. In France, where early access prior to marketing authorisation had been refused, applications are currently being made to the French National Authority for Health to facilitate the availability of the drug without waiting for the outcome of price negotiations.
